Clinical Trial Update: Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers [Phase 1, Phase 2]

View source ↗

Summary

Regeneron is conducting a Phase 1/2 trial of REGN4018 (Ubamatamab) alone or in combination with cemiplimab in adults with recurrent MUC16-expressing cancers, in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer
• Fallopian Tube Cancer
• Low-grade Serous Ovarian Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Cemiplimab (Libtayo) (cemiplimab)
• REGN4018 (Ubamatamab) (Ubamatamab)

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Recurrent Ovarian Cancer, Recurrent Fallopian Tube Cancer | Phase 1, Phase 2 | Status: RECRUITING